To address the issues with the current nomenclature of psychotropic agents, which may be misleading or confusing, the Neuroscience-based Nomenclature (NbN) started being developed in 2009. It was introduced as one approach to the classification of pharmacological treatments based on a medication’s putative psychopharmacological mechanisms of action derived from preclinical and clinical studies. In 2018, the NbN-Child & Adolescent (NbN C&A) was released. Since then, the NbN C&A has been refined, and its website and app (https://nbnca.com/) have been implemented. JAACAP encourages its authors and readers to consider utilizing the NbN C&A and to keep abreast of its developments over time. This is in line with the core missions of the Journal: to contribute to the translation and implementation of the most up-to-date science into real-world clinical practice.

Diversity & Inclusion Statement

One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented racial and/or ethnic groups in science.

中文翻译：

---

基于神经科学的儿童和青少年 (NbN C&A) 精神药物命名法：创新正在进行中

为了解决当前的精神药物命名法可能具有误导性或混淆性的问题，基于神经科学的命名法 (NbN) 于 2009 年开始开发。它是基于药物推定的药物治疗分类的一种方法。来自临床前和临床研究的精神药理学作用机制。2018年，发布了NbN-Child & Adolescent (NbN C&A)。此后，NbN C&A 得到了完善，其网站和应用程序（https://nbnca.com/）已经实施。JAACAP鼓励其作者和读者考虑使用 NbN C&A 并随时了解其发展。这符合《华尔街日报》的核心使命：为将最新的科学转化和实施到现实世界的临床实践中做出贡献。

多元化与包容性声明

本文的一位或多位作者自我认定为科学界一个或多个历史上代表性不足的种族和/或族裔群体的成员。